These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35933083)

  • 1. Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: A randomized double-blind active-controlled trial.
    Pervez MA; Khan DA; Mirza SA; Slehria AUR; Nisar U; Aamir M
    Complement Ther Med; 2022 Nov; 70():102866. PubMed ID: 35933083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled trial.
    Pervez MA; Khan DA; Slehria AUR; Ijaz A
    Complement Ther Med; 2020 Aug; 52():102494. PubMed ID: 32951743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease.
    Pervez MA; Khan DA; Ijaz A; Khan S
    Turk J Gastroenterol; 2018 Mar; 29(2):170-176. PubMed ID: 29749323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepato-Protective Effects of Delta-Tocotrienol and Alpha-Tocopherol in Patients with Non-Alcoholic Fatty Liver Disease: Regulation of Circulating MicroRNA Expression.
    Pervez MA; Khan DA; Gilani STA; Fatima S; Ijaz A; Nida S
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Beneficial effects of supplementation with microalgae Chlorella vulgaris: A double-blind placebo-controlled randomized clinical trial.
    Ebrahimi-Mameghani M; Sadeghi Z; Abbasalizad Farhangi M; Vaghef-Mehrabany E; Aliashrafi S
    Clin Nutr; 2017 Aug; 36(4):1001-1006. PubMed ID: 27475283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. δ-Tocotrienol in Combination with Resveratrol Improves the Cardiometabolic Risk Factors and Biomarkers in Patients with Metabolic Syndrome: A Randomized Controlled Trial.
    Fatima S; Khan DA; Aamir M; Pervez MA; Fatima F
    Metab Syndr Relat Disord; 2023 Feb; 21(1):25-34. PubMed ID: 36125447
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-inflammatory γ- and δ-tocotrienols improve cardiovascular, liver and metabolic function in diet-induced obese rats.
    Wong WY; Ward LC; Fong CW; Yap WN; Brown L
    Eur J Nutr; 2017 Feb; 56(1):133-150. PubMed ID: 26446095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
    Barchetta I; Del Ben M; Angelico F; Di Martino M; Fraioli A; La Torre G; Saulle R; Perri L; Morini S; Tiberti C; Bertoccini L; Cimini FA; Panimolle F; Catalano C; Baroni MG; Cavallo MG
    BMC Med; 2016 Jun; 14():92. PubMed ID: 27353492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.
    Hosseinpour-Arjmand S; Amirkhizi F; Ebrahimi-Mameghani M
    J Clin Pharm Ther; 2019 Apr; 44(2):258-267. PubMed ID: 30585337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised placebo controlled trial of VSL#3
    Chong PL; Laight D; Aspinall RJ; Higginson A; Cummings MH
    BMC Gastroenterol; 2021 Apr; 21(1):144. PubMed ID: 33794784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.
    Polyzos SA; Kountouras J; Mantzoros CS; Polymerou V; Katsinelos P
    Diabetes Obes Metab; 2017 Dec; 19(12):1805-1809. PubMed ID: 28452101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial.
    Mansour A; Mohajeri-Tehrani MR; Samadi M; Qorbani M; Merat S; Adibi H; Poustchi H; Hekmatdoost A
    Nutr J; 2021 Apr; 20(1):35. PubMed ID: 33838673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genistein supplementation improves insulin resistance and inflammatory state in non-alcoholic fatty liver patients: A randomized, controlled trial.
    Amanat S; Eftekhari MH; Fararouei M; Bagheri Lankarani K; Massoumi SJ
    Clin Nutr; 2018 Aug; 37(4):1210-1215. PubMed ID: 28647291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of total anthocyanin-base standardized (Cornus mas L.) fruit extract on liver function, tumor necrosis factor α, malondealdehyde, and adiponectin in patients with non-alcoholic fatty liver: a study protocol for a double-blind randomized clinical trial.
    Sangsefidi ZS; Hosseinzadeh M; Ranjbar AM; Akhondi-Meybodi M; Fallahzadeh H; Mozaffari-Khosravi H
    Nutr J; 2019 Jul; 18(1):39. PubMed ID: 31324181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of saffron supplementation on some inflammatory and oxidative markers, leptin, adiponectin, and body composition in patients with nonalcoholic fatty liver disease: A double-blind randomized clinical trial.
    Pour FK; Aryaeian N; Mokhtare M; Mirnasrollahi Parsa RS; Jannani L; Agah S; Fallah S; Moradi N
    Phytother Res; 2020 Dec; 34(12):3367-3378. PubMed ID: 32798261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the efficacy of tocotrienol-rich fraction vitamin E in obese children with non-alcoholic fatty liver disease: a single-blind, randomized clinical trial.
    Al-Baiaty FDR; Ishak S; Mohd Zaki F; Masra F; Abdul Aziz DA; Wan Md Zin WN; Yee Hing E; Kuthubul Zaman AS; Abdul Wahab N; Muhammad Nawawi KN; Hamid Z; Raja Ali RA; Mokhtar NM
    BMC Pediatr; 2024 Aug; 24(1):529. PubMed ID: 39160468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Chehrehgosha H; Sohrabi MR; Ismail-Beigi F; Malek M; Reza Babaei M; Zamani F; Ajdarkosh H; Khoonsari M; Fallah AE; Khamseh ME
    Diabetes Ther; 2021 Mar; 12(3):843-861. PubMed ID: 33586120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
    Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
    Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial.
    Sharifi N; Amani R; Hajiani E; Cheraghian B
    Endocrine; 2014 Sep; 47(1):70-80. PubMed ID: 24968737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Luo Q; Wei R; Cai Y; Zhao Q; Liu Y; Liu WJ
    Front Med (Lausanne); 2022; 9():793203. PubMed ID: 35280867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.